Valuation Review: Ziopharm Oncology In (ZIOP) and Celldex Therapeutics (CLDX)

Lloyd Doyle
January 12, 2018

Below is a list of ZIOPHARM Oncology, Inc. Raymond James Financial restated a "hold" rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th.

Analysts expect ZIOPHARM Oncology, Inc. Zacks Investment Research raised shares of ZIOPHARM Oncology from a hold rating to a buy rating and set a $5.25 price objective for the company in a research note on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company.

Taking a broader look at the analyst consensus, brokerage firms have a price target of $12.5 on Ziopharm Oncology In (NASDAQ:ZIOP). The Price to Sales (P/S) of the company is 34.96, while P/B (Price to Book) stands at 1.69. Analysts believe that we could see stock price minimum in the $1.4 range (lowest target price), allowing for another 5.26% jump from its current position. Many stock enthusiasts will also keep a sharp focus on positive estimate revisions to help gain an edge in the markets. The stock is now has its Return on Assets (ROA) value of -62.8 Percent. According to the Analysts, the Low Earnings estimate for the current quarter is $0.62, while the High earnings estimate is $0.78.Comparatively, EPS for the same quarter a year ago was $0.91. However the low revenue estimates for the company are $1.46 Million versus high revenue estimates of $1.7 Million. The company's revenue for the quarter was up.0% on a year-over-year basis. The company's revenue was up.0% compared to the same quarter last year. research analysts predict that ZIOPHARM Oncology will post -0.54 earnings per share for the current year.

In other news, CEO Laurence James Neil Cooper purchased 6,440 shares of the business's stock in a transaction on Wednesday, November 8th. The company's Relative Strength Index which shows price strength now stands at 51.49. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The recent price momentum makes it one stock to watch in recent days.

ZIOPHARM Oncology, Inc.'s Average Earnings Estimate for the current quarter is $-0.13, according to consensus of 4 analysts. Ziopharm Oncology In (NASDAQ:ZIOP) has a market capitalization of $586.29 Million and most recently 141.96 Million outstanding shares have been calculated. The short interest to Ziopharm Oncology Incorporated's float is 32.99%. Amalgamated Bank now owns 16,807 shares of the biotechnology company's stock valued at $105,000 after purchasing an additional 1,924 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of ZIOPHARM Oncology by 3.0% during the 2nd quarter.

Looking at Recommendation Trends of the stock polled by Reuters. Amalgamated Bank increased its position in ZIOPHARM Oncology by 12.9% during the 2nd quarter. Currently, the 200-day MA for Ziopharm Oncology In (ZIOP) is sitting at 5.70.

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company's synthetic immuno-oncology platform employs an inducible gene-delivery system that enables controlled in vivo expression of genes that produce therapeutic proteins to treat cancer.

Other reports by Iphone Fresh

Discuss This Article